Departments of Medicine and Hematology, Hadassah-Hebrew-University Medical Center, Mt Scopus, Jerusalem.
Departments of Medicine and Hematology, Hadassah-Hebrew-University Medical Center, Mt Scopus, Jerusalem.
Can J Cardiol. 2018 Nov;34(11):1534.e1-1534.e3. doi: 10.1016/j.cjca.2018.08.001. Epub 2018 Aug 6.
Current guidance recommends avoiding concomitant use of direct-acting oral anticoagulants and enzyme-inducing antiepileptic drugs because of theoretical drug interactions potentially leading to subtherapeutic drug concentrations and treatment failure. We describe a case documenting a significant interaction between phenobarbital and rivaroxaban, and then apixaban. This case illustrates and supports the concerns regarding concomitant use of these medications. Additionally, in this case the interaction was managed with concentration-guided dosing of apixaban, suggesting this approach may represent a feasible strategy for managing patients requiring treatment with direct-acting oral anticoagulants and enzyme-inducing antiepileptic drugs.
目前的指南建议避免同时使用直接作用的口服抗凝剂和酶诱导型抗癫痫药物,因为理论上的药物相互作用可能导致治疗药物浓度低于治疗范围和治疗失败。我们描述了一个案例,记录了苯巴比妥与利伐沙班,然后是阿哌沙班之间的显著相互作用。该案例说明了并支持了同时使用这些药物的担忧。此外,在这种情况下,通过阿哌沙班的浓度指导剂量来管理这种相互作用,表明这种方法可能代表了管理需要使用直接作用的口服抗凝剂和酶诱导型抗癫痫药物的患者的一种可行策略。